Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company pioneering allosteric modulation-based drug development,
Tags :Daniel Raun
Andermatt Swiss Alps has entered into a CHF 125 million revolving credit facility with Credit Suisse (Switzerland) acting as arranger, agent and lender and a&
Santhera Pharmaceuticals Holding has announced the grant of an exclusive North America license for the commercialization of vamorolone to Catalyst Pharmaceuticals for a total consideration of up to USD 231 million
Ironwood Pharmaceuticals (Nasdaq: IRWD), a healthcare company specializing in GI treatments, and VectivBio Holding (Nasdaq: VECT), a clinical-stage biopharmaceutical company focused on developing innovative therapies for severe rare gastrointestinal conditions, have reached an agreement where&
Orascom Development Holding successfully completed a capital increase in the amount of CHF 135 million. The transaction consisted of
Private investment house Ardian entered into an agreement to invest in the Swiss Flowable Holding and its subsidiaries (“Mimacom Flowable Group”) along
The US-based payments specialist Shift4, a publicly-traded global leader in commerce technology solutions, has acquired Online Payments Group, which operates the online payments platform
Meyer Burger Technology successfully completed a capital increase raising gross proceeds of approximately CHF 250 million. The transaction consisted
Monte Valle Partners and M3 Groupe Management have completed the acquisition of an unknown minority stake and majority stake respectively in TradeXBank from Sberbank of Russia Advestra has acted as legal counsel for
Viseca has sold Contovista, a Swiss fintech company focus in data-based banking, to Finnova. Finnova, a Lenzburg-based banking software manufacturer, is taking over Contovista, based in Schlieren (Zurich), with retroactive effect
